Literature DB >> 4614898

Clinical trial of isophosphamide (NSC-109724)--results and side effects.

D N Bremner, J S McCormick, J W Thomson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4614898

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  7 in total

1.  Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.

Authors:  J Ninane; R Baurain; J de Kraker; A Ferster; A Trouet; G Cornu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.

Authors:  C I Falkson; H C Falkson; G Falkson
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

3.  High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.

Authors:  R C Stuart-Harris; P G Harper; C A Parsons; S B Kaye; C A Mooney; N F Gowing; E Wiltshaw
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.

Authors:  B M Cantwell; J Carmichael; S Ghani; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Ifosfamide cardiotoxicity in humans.

Authors:  K Kandylis; M Vassilomanolakis; S Tsoussis; A P Efremidis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.

Authors:  R Skinner; S J Cotterill; M C Stevens
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

7.  A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.

Authors:  T J Perren; E Wiltshaw; P Harper; M Slevin; R Stein; S Tan; M Gore; I J Fryatt; P R Blake
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.